CTOs on the Move

HumanTouch

www.humantouch.com

 
Human Touch is the leading provider of high-quality, innovative lifestyle products, massage chairs, and experiences that deliver life-changing benefits. We have been making people feel better for over 35 years by developing state-of-the-art massage products containing patented massage systems that replicate techniques used by massage professionals. Our wellness solutions help to reduce muscle tension and pain caused by today`s hectic lifestyle so that people can do what they do - better. Combining advanced technology and attractive design, Human Touch innovations are perfectly suited for today`s modern and traditional living spaces. Our customers include serious athletes looking to recover from intensive ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Les Buday
Director of Cybersecurity Profile

Similar Companies

Annapolis Yacht Club

Welcome to Annapolis Yacht Club Junior sailing page. Keep up with the activities of the Junior Sailing program throughout the year.

Ashley Glen Assisted Living

Ashley Glen Assisted Living is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Complete Home Health Inc

Complete Home Health Inc is a Lafayette, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bert Fish Medical Center

Bert Fish Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Bert Fish Medical Center is based in New Smyrna Beach, FL. You can find more information on Bert Fish Medical Center at www.bertfish.com

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.